Medtronic CEO Tinkers With Organization To Begin New Fiscal Year
This article was originally published in The Gray Sheet
Executive Summary
Medtronic CEO Bill Hawkins removed the management layer between himself and the firm's business units, created a new position in charge of overseas operations, and replaced the spinal division president as part of a series of organizational changes announced April 29
You may also be interested in...
People In Brief
Lanx gets DeMane: Former Medtronic Chief Operating Officer Michael DeMane is now the chairman and CEO of spine device firm Lanx, the privately held company announced June 7. DeMane moves from his post at venture capital firm Thomas, McNerney and Partners, which he joined last year following his departure from Medtronic in 2008, when the firm eliminated its COO post (1"The Gray Sheet" May 5, 2008). He was an executive at Smith & Nephew and then spine firm Sofamor Danek Group until Medtronic acquired Sofamor in 1999. DeMane subsequently ran Medtronic's spinal systems business. In 2005, he took the helm of Medtronic's Europe, Canada, Latin America and Emerging Markets division, prior to becoming COO in 2007. Lanx markets 10 spinal fusion product lines, including the Telluride minimally invasive system and the BioLanx biologics line
People In Brief
Lanx gets DeMane: Former Medtronic Chief Operating Officer Michael DeMane is now the chairman and CEO of spine device firm Lanx, the privately held company announced June 7. DeMane moves from his post at venture capital firm Thomas, McNerney and Partners, which he joined last year following his departure from Medtronic in 2008, when the firm eliminated its COO post (1"The Gray Sheet" May 5, 2008). He was an executive at Smith & Nephew and then spine firm Sofamor Danek Group until Medtronic acquired Sofamor in 1999. DeMane subsequently ran Medtronic's spinal systems business. In 2005, he took the helm of Medtronic's Europe, Canada, Latin America and Emerging Markets division, prior to becoming COO in 2007. Lanx markets 10 spinal fusion product lines, including the Telluride minimally invasive system and the BioLanx biologics line
People In Brief
Administration reform post: Michael Hash, a former deputy administrator at the Health Care Financing Administration (now CMS), has joined the administration in a top-level role in health care reform. Hash's responsibilities will include coordinating reform activities between the White House Office of Health Reform and the Department of Health and Human Services. Hash was most recently a principal at Health Policy Alternatives, a Washington-based consulting firm. He was at HCFA from 1998 to 2000 and served as deputy to Nancy-Ann DeParle, now director of the White House health reform office (1"The Gray Sheet" March 9, 2009, p. 9)